Ines De Mesmaeker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ines De Mesmaeker has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Pipeleers
Diabetes Research Center, Vrije Universiteit Brussel (VUB), Brussels, Belgium
7 shared publications Zhidong Ling
Diabetes Research Center, Free University Brussels – VUB, Belgium
6 shared publications- Geert Stangé
Diabetes Research Center, Free University Brussels – VUB, Belgium
5 shared publications - Bart Keymeulen
Diabetes Research Center, Vrije Universiteit Brussel (VUB), Brussels, Belgium
4 shared publications - Thomas Robert
Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium
4 shared publications - Daniel Jacobs-Tulleneers-Thevissen
Diabetes Research Center, Vrije Universiteit Brussel (VUB), Brussels, Belgium
3 shared publications
Latest Publications
- Open Access
- 4 November 2021
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (3) , 927-936
Function and composition of pancreatic islet cell implants in omentum of type 1 diabetes patients
- 4 November 2021
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (3) , 927-936
Open AccessFunction and composition of pancreatic islet cell implants in omentum of type 1 diabetes patients
- Open Access
- 18 November 2020
- Published by Elsevier in American Journal of Transplantation
- Vol. 21 (6) , 2090-2099
Formation of amyloid in encapsulated human pancreatic and human stem cell-generated beta cell implants
- 18 November 2020
- Published by Elsevier in American Journal of Transplantation
- Vol. 21 (6) , 2090-2099
Open AccessFormation of amyloid in encapsulated human pancreatic and human stem cell-generated beta cell implants
- Open Access
- 4 August 2019
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 8 (12) , 1296-1305
Cell Mass Increase Associated with Formation of Glucose-Controlling β-Cell Mass in Device-Encapsulated Implants of hiPS-Derived Pancreatic Endoderm
Device-encapsulated human stem cell-derived pancreatic endoderm (PE) can generate functional β-cell implants in the subcutis of mice, which has led to the start of clinical studies in type 1 diabetes. Assessment of the formed functional β-cell mass (FBM) and its correlation with in vivo metabolic markers can guide clinical translation. We recently reported ex vivo characteristics of device-encapsulated human embryonic stem cell-derived (hES)-PE implants in mice that had established a metabolically adequate FBM during 50-week follow-up. Cell suspensions from retrieved implants indicated a correlation with the number of formed β cells and their maturation to a functional state comparable to human pancreatic β cells. Variability in metabolic outcome was attributed to differences in number of PE-generated β cells. This variability hinders studies on processes involved in FBM-formation. This study reports modifications that reduce variability. It is undertaken with device-encapsulated human induced pluripotent stem cell-derived-PE subcutaneously implanted in mice. Cell mass of each cell type was determined on intact tissue inside the device to obtain more precise data than following isolation and dispersion. Implants in a preformed pouch generated a glucose-controlling β-cell mass within 20 weeks in over 60% of recipients versus less than 20% in the absence of a pouch, whether the same or threefold higher cell dose had been inserted. In situ analysis of implants indicated a role for pancreatic progenitor cell expansion and endocrine differentiation in achieving the size of β- and α-cell mass that correlated with in vivo markers of metabolic control. Stem Cells Translational Medicine 2019;8:1296&1305
- 4 August 2019
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 8 (12) , 1296-1305
Open AccessCell Mass Increase Associated with Formation of Glucose-Controlling β-Cell Mass in Device-Encapsulated Implants of hiPS-Derived Pancreatic Endoderm
Device-encapsulated human stem cell-derived pancreatic endoderm (PE) can generate functional β-cell implants in the subcutis of mice, which has led to the start of clinical studies in type 1 diabetes. Assessment of the formed functional β-cell mass (FBM) and its correlation with in vivo metabolic markers can guide clinical translation. We recently reported ex vivo characteristics of device-encapsulated human embryonic stem cell-derived (hES)-PE implants in mice that had established a metabolically adequate FBM during 50-week follow-up. Cell suspensions from retrieved implants indicated a correlation with the number of formed β cells and their maturation to a functional state comparable to human pancreatic β cells. Variability in metabolic outcome was attributed to differences in number of PE-generated β cells. This variability hinders studies on processes involved in FBM-formation. This study reports modifications that reduce variability. It is undertaken with device-encapsulated human induced pluripotent stem cell-derived-PE subcutaneously implanted in mice. Cell mass of each cell type was determined on intact tissue inside the device to obtain more precise data than following isolation and dispersion. Implants in a preformed pouch generated a glucose-controlling β-cell mass within 20 weeks in over 60% of recipients versus less than 20% in the absence of a pouch, whether the same or threefold higher cell dose had been inserted. In situ analysis of implants indicated a role for pancreatic progenitor cell expansion and endocrine differentiation in achieving the size of β- and α-cell mass that correlated with in vivo markers of metabolic control. Stem Cells Translational Medicine 2019;8:1296&1305
- 10 October 2018
- Published by American Diabetes Association in Diabetes
- Vol. 67 (12) , 2640-2649
Increase Functional β-Cell Mass in Subcutaneous Alginate Capsules With Porcine Prenatal Islet Cells but Loss With Human Adult Islet Cells
Alginate-encapsulated porcine islet cell grafts are developed to overcome limitations of human islet transplantation. They can generate functional implants in animals when prepared from fetal, perinatal and adult pancreases. Implants have not yet been examined for efficacy to establish sustained metabolically-adequate functional beta cell mass (FBM) with comparison to human islet cells. This study in immune-compromised mice demonstrates that subcutaneous implants of Alg-porcine-prenatal islet cells with 4x105 beta cells form, over 10 weeks, a FBM that results in glucose-induced plasma C-peptide >2 ng/mL and metabolic control over the following 10 weeks, with higher efficiency than non-encapsulated, while failing in peritoneum. This intracapsular FBM-formation involves beta cell replication, increasing number 4-fold, and maturation towards human adult beta cells. Subcutaneous Alg-human islet cells with similar beta cell number establish implants with plasma C-peptide >2 ng/mL for the first 10 weeks, while failing non-encapsulated; their beta cells do not replicate but progressively die (>70%) explaining C-peptide decline and insufficient metabolic control. An alginate matrix thus helps establish beta cell functions in subcutis. It allows formation of sustained metabolically-adequate FBM by immature porcine beta cells with proliferative activity but not by human adult islet cells. These findings define conditions for evaluating its immune-protecting properties.
- 10 October 2018
- Published by American Diabetes Association in Diabetes
- Vol. 67 (12) , 2640-2649
Increase Functional β-Cell Mass in Subcutaneous Alginate Capsules With Porcine Prenatal Islet Cells but Loss With Human Adult Islet Cells
Alginate-encapsulated porcine islet cell grafts are developed to overcome limitations of human islet transplantation. They can generate functional implants in animals when prepared from fetal, perinatal and adult pancreases. Implants have not yet been examined for efficacy to establish sustained metabolically-adequate functional beta cell mass (FBM) with comparison to human islet cells. This study in immune-compromised mice demonstrates that subcutaneous implants of Alg-porcine-prenatal islet cells with 4x105 beta cells form, over 10 weeks, a FBM that results in glucose-induced plasma C-peptide >2 ng/mL and metabolic control over the following 10 weeks, with higher efficiency than non-encapsulated, while failing in peritoneum. This intracapsular FBM-formation involves beta cell replication, increasing number 4-fold, and maturation towards human adult beta cells. Subcutaneous Alg-human islet cells with similar beta cell number establish implants with plasma C-peptide >2 ng/mL for the first 10 weeks, while failing non-encapsulated; their beta cells do not replicate but progressively die (>70%) explaining C-peptide decline and insufficient metabolic control. An alginate matrix thus helps establish beta cell functions in subcutis. It allows formation of sustained metabolically-adequate FBM by immature porcine beta cells with proliferative activity but not by human adult islet cells. These findings define conditions for evaluating its immune-protecting properties.
- Open Access
- 1 March 2018
- Published by Elsevier in Stem Cell Reports
- Vol. 10 (3) , 739-750
Functional Beta Cell Mass from Device-Encapsulated hESC-Derived Pancreatic Endoderm Achieving Metabolic Control
- 1 March 2018
- Published by Elsevier in Stem Cell Reports
- Vol. 10 (3) , 739-750
Open AccessFunctional Beta Cell Mass from Device-Encapsulated hESC-Derived Pancreatic Endoderm Achieving Metabolic Control
- Open Access
- 15 August 2017
- Published by Springer Nature in Current Diabetes Reports
- Vol. 17 (10) , 1-7
Heterogeneity in the Beta-Cell Population: a Guided Search Into Its Significance in Pancreas and in Implants
Purpose of Review Intercellular differences in function have since long been noticed in the pancreatic beta-cell population. Heterogeneity in cellular glucose responsiveness is considered of physiological and pathological relevance. The present review updates evidence for the physiologic significance of beta-cell heterogeneity in the pancreas. It also briefly discusses what this role would imply for beta-cell implants in diabetes. Recent Findings Over the past 3 years, functionally different beta cells have been related to mechanisms that may underlie their heterogeneity in the pancreas, such as the stage in their life cycle and the degree of their clustering to islets with varying vascularization. Markers were identified for detecting these subpopulations in tissues. Summary The existence of a functional heterogeneity in the pancreatic beta-cell population is further supported. Views on its origin and methods for its analysis in pancreas and implants will help guide the search into its significance in beta-cell biology, pathology, and therapy.
- 15 August 2017
- Published by Springer Nature in Current Diabetes Reports
- Vol. 17 (10) , 1-7
Open AccessHeterogeneity in the Beta-Cell Population: a Guided Search Into Its Significance in Pancreas and in Implants
Purpose of Review Intercellular differences in function have since long been noticed in the pancreatic beta-cell population. Heterogeneity in cellular glucose responsiveness is considered of physiological and pathological relevance. The present review updates evidence for the physiologic significance of beta-cell heterogeneity in the pancreas. It also briefly discusses what this role would imply for beta-cell implants in diabetes. Recent Findings Over the past 3 years, functionally different beta cells have been related to mechanisms that may underlie their heterogeneity in the pancreas, such as the stage in their life cycle and the degree of their clustering to islets with varying vascularization. Markers were identified for detecting these subpopulations in tissues. Summary The existence of a functional heterogeneity in the pancreatic beta-cell population is further supported. Views on its origin and methods for its analysis in pancreas and implants will help guide the search into its significance in beta-cell biology, pathology, and therapy.
- Open Access
- 5 July 2016
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 5 (10) , 1338-1344
Concise Review: Markers for Assessing Human Stem Cell-Derived Implants as β-Cell Replacement in Type 1 Diabetes
A depleted β-cell mass causes diabetes complications that cannot be avoided by insulin administration. β-Cell replacement can stop their development when restoring insulin's homeostatic role. This requires a sufficient number and an adequate functional state of the β cells, together defined as “functional β-cell mass.” Intraportal implants of human pancreatic islet cells correct hyperglycemia in patients with type 1 diabetes, but this effect is transient and often incomplete. Studies to improve outcome are hindered by shortage in donor pancreases. Human pluripotent stem cells are a candidate source for mass production of grafts for β-cell replacement. Their in vitro differentiation to pancreatic endoderm (stage 4) and to β-cell-containing preparations (stage 7) provides grafts that generate β-cell implants in mice. In vivo markers indicated a better outcome of device-encapsulated stage 4 cells and microencapsulated stage 7 cells as compared with nonencapsulated grafts. Encapsulation also offers the advantage of representative implant retrieval for direct analysis by ex vivo markers. Combination of in vitro, in vivo, and ex vivo markers allows comparison of different stem cell-derived grafts and implants, with each other and with clinical islet cell preparations that serve as reference. Data in mice provide insights into the biology of stem cell-generated β-cell implants, in particular their capacity to establish and sustain a functional β-cell mass. They can thus be indicative for translation of a graft to similar studies in patients, where metabolic benefit will be an additional marker of primordial importance. Significance: Human stem cell-derived preparations can generate insulin-producing implants in immune-incompetent mice. Steps are undertaken for translation to patients with type 1 diabetes. Their therapeutic significance will depend on their capacity to establish a functional β-cell mass that provides metabolic benefit. This study proposes the combined use of in vitro, in vivo, and ex vivo markers to assess this potential in preclinical models and in clinical studies.
- 5 July 2016
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 5 (10) , 1338-1344
Open AccessConcise Review: Markers for Assessing Human Stem Cell-Derived Implants as β-Cell Replacement in Type 1 Diabetes
A depleted β-cell mass causes diabetes complications that cannot be avoided by insulin administration. β-Cell replacement can stop their development when restoring insulin's homeostatic role. This requires a sufficient number and an adequate functional state of the β cells, together defined as “functional β-cell mass.” Intraportal implants of human pancreatic islet cells correct hyperglycemia in patients with type 1 diabetes, but this effect is transient and often incomplete. Studies to improve outcome are hindered by shortage in donor pancreases. Human pluripotent stem cells are a candidate source for mass production of grafts for β-cell replacement. Their in vitro differentiation to pancreatic endoderm (stage 4) and to β-cell-containing preparations (stage 7) provides grafts that generate β-cell implants in mice. In vivo markers indicated a better outcome of device-encapsulated stage 4 cells and microencapsulated stage 7 cells as compared with nonencapsulated grafts. Encapsulation also offers the advantage of representative implant retrieval for direct analysis by ex vivo markers. Combination of in vitro, in vivo, and ex vivo markers allows comparison of different stem cell-derived grafts and implants, with each other and with clinical islet cell preparations that serve as reference. Data in mice provide insights into the biology of stem cell-generated β-cell implants, in particular their capacity to establish and sustain a functional β-cell mass. They can thus be indicative for translation of a graft to similar studies in patients, where metabolic benefit will be an additional marker of primordial importance. Significance: Human stem cell-derived preparations can generate insulin-producing implants in immune-incompetent mice. Steps are undertaken for translation to patients with type 1 diabetes. Their therapeutic significance will depend on their capacity to establish a functional β-cell mass that provides metabolic benefit. This study proposes the combined use of in vitro, in vivo, and ex vivo markers to assess this potential in preclinical models and in clinical studies.